Relevant bibliographies by topics / SLEDAI

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'SLEDAI'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'SLEDAI.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "SLEDAI"

1

Jesus, D., A. Matos, C. Henriques, A. Doria, and L. Inês. "POS0762 CAN THE SLE-DAS SUBSTITUTE BILAG TO MEASURE LUPUS DISEASE ACTIVITY IN CLINICAL TRIALS? POST-HOC ANALYSIS OF THE BLISS-76 TRIAL." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 634.2–635. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3162.

Full text
Abstract:
Background:The primary endpoint for randomized clinical trials (RCT) in Systemic lupus erythematosus (SLE) is usually defined as proportion of responders in a composite index. The most widely used are British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Responder Index (SRI). Both comprise BILAG along with SLE Disease Activity Index (SLEDAI). BICLA and SRI are complex and time-consuming to assess.The SLE Disease Activity Score (SLE-DAS) is an easy to apply, validated, continuous disease activity measure, highly correlated with SLEDAI, with higher accuracy and sensitivity-to-change as compared to SLEDAI1.We hypothesize that SLE-DAS can also identify the SLE disease activity information from BILAG, thus dispensing the use of composite indexes for RCT.Objectives:To compare the ability of the SLE-DAS and the Safety of Estrogen in Lupus National Assessment (SELENA)-SLEDAI to discriminate between BILAG classification of mild vs. moderate vs. severe disease activity.Methods:Post-hoc analysis of all intention-to-treat patients in the BLISS-76 (NCT00410384) RCT at the baseline study visit. SELENA-SLEDAI and BILAG were assessed at time of the study visits and SLE-DAS was retrospectively scored from the study database. Patients’ disease activity was classified as: (i) mild (no BILAG B or A scores in any organ domain); (ii) moderate (1 BILAG B, no A scores); (iii) severe (≥2 BILAG B and/or ≥1 BILAG A). Ability of the SLE-DAS and SELENA-SLEDAI to differentiate between: (i) mild vs. moderate/severe disease activity; (ii) mild/moderate vs. severe disease activity (according to BILAG), were evaluated using receiver operating characteristic (ROC) analysis. The area under the ROC curves (AUCs) with 95% confidence intervals (95%CI) as a measure of discriminatory ability of the SLE-DAS and SELENA-SLEDAI were compared using Delong’s test for two correlated curves. Because AUC measurements might have restricted accuracy for imbalanced datasets, precision-recall (PR) curves and area under PR curves (AUC-PR) were also performed. Statistical significance was set at 0.05.Results:We included 819 patients, classified by BILAG as presenting mild (7.7%), moderate (28.8%) or severe (63.5%) disease activity. To differentiate mild vs. moderate/severe disease activity, the discriminatory ability of SLE-DAS was outstanding (AUC 0.948; 95%CI 0.923-0.973), while that of SELENA-SLEDAI was acceptable (AUC 0.729; 95%CI 0.657-0.801) (p<0.005) (figure 1A). To differentiate mild/moderate vs. severe disease activity, the discriminatory ability of SLE-DAS was excellent (AUC 0.873; 95%CI 9.846-0.899), while that of SELENA-SLEDAI was acceptable (AUC 0.707; 95%CI 0.670-0.744) (p<0.005) (figure 1B). The AUC-PR confirmed the higher performance of SLE-DAS over SELENA-SLEDAI to differentiate mild vs. moderate/severe disease activity (0.995 vs. 0.965, respectively) (figure 1C) and mild/moderate vs. severe disease activity (0.902 vs. 0.794, respectively) (figure 1D).Figure 1.Receiver operating characteristics (ROC) curves comparing the ability of the SLE-DAS and SELENA-SLEDAI to differentiate (A) mild vs. moderate/severe disease activity and (B) mild/moderate vs. severe disease activity, as assessed by BILAG; and Precision-recall (PR) curves comparing the performance of the SLE-DAS and SELENA-SLEDAI to differentiate (C) mild vs. moderate/severe disease activity and (D) mild/moderate vs. severe disease activity.Conclusion:The SLE-DAS presents excellent performance in assessing SLE disease activity categorized by BILAG scores, which is not the case for SELENA-SLEDAI. Further studies will aim to better define ability of SLE-DAS to substitute composite responder indices.References:[1]Jesus D, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis 2019;78:365-71.Acknowledgements:The authors would like to thank GlaxoSmithKline (Uxbridge, UK) for granting access to the data from the BLISS-76 trial through the Clinical Study Data Request consortium.Disclosure of Interests:None declared
APA, Harvard, Vancouver, ISO, and other styles
2

Schned, Eric S., Scott L. Glickstein, and M. Thomas Anne Doyle. "Derivation of the sledai." Arthritis & Rheumatism 36, no. 6 (1993): 877. http://dx.doi.org/10.1002/art.1780360623.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ya Fatwa Pulungan, Rizki Luly, Ratna Akbari Ganie, and Zuhrial Zubir. "Interleukin-34 and Disease Activity in Systemic Lupus Erythematosus Patients." INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY 27, no. 2 (2021): 196. http://dx.doi.org/10.24293/ijcpml.v27i2.1636.

Full text
Abstract:
Systemic Lupus Erythematosus (SLE) is characterized by exacerbation and remission, which needs close monitoring ofthe disease activity. Systemic lupus erythematosus disease activity can be determined by the SLE Disease Activity Index(SLEDAI) score. Evaluation of the disease activity is essential to be a guidance for treatment. Interleukin-34 (IL-34) is relatedto the pathogenesis of SLE. Serum IL-34 can be a candidate marker to evaluate SLE disease activity, and it is correlated withthe SLEDAI score. This study aimed to determine the correlation between IL-34 level and disease activity in SLE patientsbased on the SLEDAI (Mex-SLEDAI) score. An observational analytical study with a cross-sectional design was carried out insix months (June-November 2019) in 27 SLE patients in the Department of Internal Medicine, Faculty of Medicine, SumateraUtara University/Adam Malik General Hospital, Medan. Systemic lupus erythematosus disease activity was measured basedon the Mex-SLEDAI score. Serum and urine were collected to obtain the Mex-SLEDAI score and IL-34 level. IL-34 level wasmeasured in all subjects by using Enzyme-Linked Immunosorbent Assay (ELISA). Spearman correlation test was used todetermine the correlation between IL-34 level and disease activity in SLE patients based on the SLEDAI (Mex-SLEDAI) score.There was a significant correlation between IL-34 level and disease activity in SLE patients based on SLEDAI (Mex-SLEDAI)score (r=0.965, p < 0.001). Further studies were needed with a sample of SLE patients in a balanced proportion based ontheir disease activity to obtain representative IL-34 levels in SLE patients based on their disease activity.
APA, Harvard, Vancouver, ISO, and other styles
4

Jesus, Diogo, Ana Matos, Carla Henriques, et al. "Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity." Annals of the Rheumatic Diseases 78, no. 3 (2019): 365–71. http://dx.doi.org/10.1136/annrheumdis-2018-214502.

Full text
Abstract:
ObjectivesTo derive and validate a new disease activity measure for systemic lupus erythematosus (SLE), the SLE Disease Activity Score (SLE-DAS), with improved sensitivity to change as compared with SLE Disease Activity Index (SLEDAI), while maintaining high specificity and easiness of use.MethodsWe studied 520 patients with SLE from two tertiary care centres (derivation and validation cohorts). At each visit, disease activity was scored using the Physician Global Assessment (PGA) and SLEDAI 2000 (SLEDAI-2K). To construct the SLE-DAS, we applied multivariate linear regression analysis in the derivation cohort, with PGA as dependent variable. The formula was validated in a different cohort through the study of: (1) correlations between SLE-DAS, PGA and SLEDAI-2K; (2) performance of SLEDAI-2K and SLE-DAS in identifying a clinically meaningful change in disease activity (ΔPGA≥0.3); and (3) accuracy of SLEDAI-2K and SLE-DAS time-adjusted means in predicting damage accrual.ResultsThe final SLE-DAS instrument included 17 items. SLE-DAS was highly correlated with PGA (r=0.875, p<0.0005) and SLEDAI-2K (r=0.943, p<0.0005) in the validation cohort. The optimal discriminative ΔSLE-DAS cut-off to detect a clinically meaningful change was 1.72. In the validation cohort, SLE-DAS showed a higher sensitivity than SLEDAI-2K (change ≥4) to detect a clinically meaningful improvement (89.5% vs 47.4%, p=0.008) or worsening (95.5% vs 59.1%, p=0.008), while maintaining similar specificities. SLE-DAS performed better in predicting damage accrual than SLEDAI-2K.ConclusionSLE-DAS has a good construct validity and has better performance than SLEDAI-2K in identifying clinically significant changes in disease activity and in predicting damage accrual.
APA, Harvard, Vancouver, ISO, and other styles
5

TOUMA, ZAHI, DAFNA D. GLADMAN, DOMINIQUE IBAÑEZ, SHAHRZAD TAGHAVI-ZADEH, and MURRAY B. UROWITZ. "Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 Enhances the Ability of SLE Responder Index to Identify Responders in Clinical Trials." Journal of Rheumatology 38, no. 11 (2011): 2395–99. http://dx.doi.org/10.3899/jrheum.110550.

Full text
Abstract:
Objective.To evaluate the performance of the Systemic Lupus Erythematosus (SLE) Responder Index (SRI) when the SLE Disease Activity Index 2000 (SLEDAI-2K) is substituted with SLEDAI-2K Responder Index-50 (SRI-50), a valid and reliable index of disease activity improvement. Also, to determine whether the SRI-50 will enhance the ability of SRI in detecting responders.Methods.Our study was conducted on patients who attended the Lupus Clinic from September 2009 to September 2010. SLEDAI-2K, SRI-50, the British Isles Lupus Assessment Group measure, and the Physician’s Global Assessment were determined initially and at followup. SRI was determined at the followup visit according to its original definition using the SLEDAI-2K score and by substituting SLEDAI-2K with SRI-50.Results.A total of 117 patients with SLEDAI-2K ≥ 4 at baseline were studied. Patients had 1 followup visit over a 3-month period. Twenty-nine percent of patients met the original definition of SRI and 35% of patients met the definition of SRI when SLEDAI-2K was substituted with SRI-50. The use of SRI-50 allowed determination of significant improvement in 7 additional patients. This improvement could not be discerned with the use of SLEDAI-2K as a component of SRI. At followup visits that showed improvement, SRI-50 scores decreased to a greater extent than SLEDAI-2K scores (p < 0.0001).Conclusion.SRI-50 enhances the ability of SRI to identify patients with clinically important improvement in disease activity. SRI-50 was superior to SLEDAI-2K in detecting partial clinical improvement, ≥ 50%, between visits. These properties of the SRI-50 enable it to be used as an independent outcome measure of improvement or as a component of SRI in clinical trials.
APA, Harvard, Vancouver, ISO, and other styles
6

Jesus, D., M. Rodrigues, A. Matos, C. Henriques, J. A. Pereira da Silva, and L. S. Inês. "Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36–month prospective cohort study of 334 patients." Lupus 28, no. 5 (2019): 607–12. http://dx.doi.org/10.1177/0961203319836717.

Full text
Abstract:
Objective The objective of this paper is to evaluate the performance of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) in detecting clinically meaningful changes in SLE disease activity. Methods A longitudinal cohort study was conducted of 334 SLE patients during a 36-month follow-up. At each outpatient visit, disease activity was scored using the Physician Global Assessment (PGA) and SLEDAI-2K. Correlations between PGA and SLEDAI-2K were assessed. A clinically meaningful change in SLE disease activity was defined as a ΔPGA ≥ 0.3 points from baseline. Performance of SLEDAI-2K in detecting a clinically meaningful worsening or improvement was tested using receiver operating characteristic (ROC) analysis. Results Adjusted mean PGA and SLEDAI-2K scores presented a high correlation (rho = 0.824, p < 0.0005). In ROC analysis, a SLEDAI-2K variation presented an area under the curve (AUC) of 0.697 (95% confidence interval (CI) (0.628–0.766), p < 0.0005) to detect a clinically meaningful improvement, with a sensitivity of 28.8% for a SLEDAI-2K ≥ 4 reduction. The AUC to detect a clinically meaningful worsening was 0.877 (95% CI (0.822–0.932), p < 0.0005), with a sensitivity of 35.3%. Conclusions SLEDAI-2K has a limited ability to detect clinically meaningful changes in SLE disease activity, failing to identify almost two-thirds of cases judged as having a clinically meaningful improvement or worsening. There is a need for more sensitive SLE disease activity measures in clinical practice and research.
APA, Harvard, Vancouver, ISO, and other styles
7

Mok, C. C., L. Y. Ho, K. L. Chan, and J. Meenakshi. "POS0769 VALIDATION OF THE SIMPLE INDEX FOR DISEASE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS IN CHINESE PATIENTS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 638.2–639. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3386.

Full text
Abstract:
Objectives:To validate the SIMPLE index for systemic lupus erythematosus (SLE) disease activity assessment in Chinese patients.Methods:Adult patients (age ≥18 years) who fulfilled the 2013 SLICC criteria for SLE and were followed in the Rheumatology clinics of Tuen Mun Hospital, Hong Kong were recruited in a cross-sectional study. Participants were invited to complete the SIMPLE questionnaire before seeing doctors on the same day. The two laboratory results were supplemented by research nurses. Physicians, who were blinded to the SIMPLE results, were asked to complete disease activity assessment by the SELENA-SLEDAI and physicians’ global assessment (PGA) after consultation. Correlation was made between the SIMPLE score and the SLEDAI/PGA scores by Spearman’s rank correlation test. Receiver operating characteristic (ROC) analysis was performed to find the best cut-off SIMPLE score that predicted a clinical SLEDAI score of 1-6 (mild SLE activity) and ≥7 (moderate/severe activity).Results:364 SLE patients were studied (94% women; age 45.4±13.4 years; disease duration 13.2±8.0 years). The proportion of patients having a history of neuropsychiatric and renal disease that required immunosuppressive therapies was 9.3% and 56%, respectively. At the time of questionnaire completion, 69 (19%) patients had SLEDAI ≥6 and 192 (53%) had SLEDAI 1-5. The mean SLEDAI was 3.04±2.85 and PGA score was 0.62±0.55. A total of 161 (44%) had SDI score ≥1. The mean SIMPLE index was 26.0±12.9. SIMPLE index correlated significantly with SLEDAI (ρ=0.76; p<0.001) and PGA score (ρ=0.48; p<0.001). ROC analysis showed that a SIMPLE index of >27 points best predicted a clinical SLEDAI score of 1-6 (area under the curve [AUC] 0.78[0.73-0.84]; sensitivity 0.75; specificity 0.71), and >36.8 points best predicted a clinical SLEDAI score of ≥7 (AUC 0.87[0.69-1.00]; sensitivity 0.88, specificity 0.85).Conclusion:SIMPLE shows a good correlation with SELENA-SLEDAI and PGA. It is a simple tool that enables patients to self-report disease activity and communicate with the health care team more efficiently.Disclosure of Interests:None declared
APA, Harvard, Vancouver, ISO, and other styles
8

Touma, Z., MB Urowitz, D. Ibañez, and DD Gladman. "SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation." Lupus 20, no. 1 (2011): 67–70. http://dx.doi.org/10.1177/0961203310385163.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ugarte-Gil, Manuel Francisco, Rocio Violeta Gamboa-Cardenas, Cristina Reátegui-Sokolova, et al. "Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort." Lupus Science & Medicine 7, no. 1 (2020): e000419. http://dx.doi.org/10.1136/lupus-2020-000419.

Full text
Abstract:
ObjectiveThe Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) clinician-reported outcome (ClinRO) and the LFA-REAL patient-reported outcome (PRO) were developed in order to capture manifestations of SLE from the perspective of both the clinician and the patient. The aim of this study is to compare the LFA-REAL ClinRO and PRO with other lupus disease activity measures.MethodsA cross-sectional analysis of patients from a single-centre cohort was performed using Spearman’s correlation. Disease activity measures included were LFA-REAL ClinRO (range 0–1400), LFA-REAL PRO (range 0–1200), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), clinical SLEDAI-2K and Physician Global Assessment (PGA, range 0–100).ResultsTwo hundred and twenty-seven patients with SLE were studied. The mean age was 46.3 (SD: 13.8); 212 (93.4%) were female. The mean (SD) LFA-REAL ClinRO was 25.4 (34.7), LFA-REAL PRO was 241.1 (187.6), PGA was 11.9 (15.4), SLEDAI-2K was 2.3 (3.3) and clinical SLEDAI-2K was 1.6 (2.9). The LFA-REAL ClinRO correlated with PGA (r=0.758, p<0.001), SLEDAI-2K (r=0.608, p<0.001) and clinical SLEDAI-2K (r=0.697, p<0.001); the LFA-REAL PRO correlated modestly with PGA (r=0.160, p=0.016), SLEDAI-2K (r=0.121, p=0.069), clinical SLEDAI-2K (r=0.143, p=0.031) and LFA-REAL ClinRO (r=0.161, p=0.015).ConclusionsThe LFA-REAL ClinRO and the LFA-REAL PRO had good and weak correlations, respectively, with several physician-based disease activity measures in a cross-sectional study, suggesting their potential usefulness in establishing disease severity. Longitudinal studies will be required to determine their value in monitoring patients with SLE.
APA, Harvard, Vancouver, ISO, and other styles
10

Trisnia, Putu Ayunda, Ketut Dewi KUmara Wati, Komang Ayu Witarini, Ida Bagus Ramajaya Sutawan, and Hendra Santoso. "Efficacy of high-dose methylprednisolone and cyclophosphamide in childhood-onset systemic lupus erythematosus." Paediatrica Indonesiana 60, no. 3 (2020): 116–23. http://dx.doi.org/10.14238/pi60.3.2020.116-23.

Full text
Abstract:
Background Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Untreated SLE often become progressive and lead to increased risk of mortality. Corticosteroid and cyclophosphamide remain the treatment of choice for severe SLE. Disease activity assessed with SLE Daily Activity Index (SLEDAI).
 Objective To compare the disease activity of childhood-onset severe SLE at the time of diagnosis, after completion of high dose methylprednisolone, and after three month of cyclophosphamide by using SLEDAI.
 Methods This study was conducted in the Division of Pediatric Allergy and Immunology, Department of Child Health, Udayana University/Sanglah Hospital, Denpasar, Bali. Subjects were SLE patient aged 0-18 years who had severe clinical manifestations. Subject received therapy combination of high dose methylprednisolone and cyclophosphamide every 2 weeks for six doses. SLEDAI score was assessed at the time of diagnosis, after completion of high dose methylprednisolone, and after three month of cyclophosphamide.
 Results During the study period, 51 children were diagnosed as SLE. Twenty-one subjects were included for analysis. Median SLEDAI score at the time of diagnosis was 23 (range 13-39). SLEDAI score after three months of cyclophosphamide was decreased to 2 (range 0-14). Post hoc analysis with Wilcoxon signed-rank test showed the improvement of SLEDAI score at the time of diagnosis and after three months of cyclophosphamide was statistically significant (Z=-4.016, P<0.0001).
 Conclusion SLEDAI score reduced after completion of high-dose methylprednisolone and three month of cyclophosphamide therapy.
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "SLEDAI"

1

Ribeiro, Daniel Lima de S?? "Associa????o dos n??veis s??ricos de CXCL 13 com achados ultrassonogr??ficos articulares em pacientes com l??pus eritematoso sist??mico e artropatia de Jaccoud." Escola Bahiana de Medicina e Sa??de P??blica, 2018. http://www7.bahiana.edu.br//jspui/handle/bahiana/2599.

Full text
Abstract:
Submitted by Carla Santos (biblioteca.cp2.carla@bahiana.edu.br) on 2018-11-20T14:06:17Z No. of bitstreams: 1 DANIEL LIMA DE S?? RIBEIRO.pdf: 15828554 bytes, checksum: f475ae99a02f0773348b7abdcc5abcd8 (MD5)<br>Approved for entry into archive by JOELMA MAIA (ebmsp-bibliotecacp2@bahiana.edu.br) on 2018-11-20T18:40:35Z (GMT) No. of bitstreams: 1 DANIEL LIMA DE S?? RIBEIRO.pdf: 15828554 bytes, checksum: f475ae99a02f0773348b7abdcc5abcd8 (MD5)<br>Made available in DSpace on 2018-11-20T18:40:35Z (GMT). No. of bitstreams: 1 DANIEL LIMA DE S?? RIBEIRO.pdf: 15828554 bytes, checksum: f475ae99a02f0773348b7abdcc5abcd8 (MD5) Previous issue date: 2018-10-17<br>O envolvimento articular ?? a manifesta????o cl??nica mais freq??ente do l??pus eritematoso sist??mico (LES). A artropatia de Jaccoud (AJ), embora menos frequente, ?? uma artrite deformante, "revers??vel", que pode ocorrer em at?? 5% desses pacientes. Objetivo: O objetivo prim??rio ?? estudar e avaliar a correla????o entre o grau de sinovite, tenossinovite e eros??es pela USG nos casos de LES com e sem AJ e os n??veis s??ricos de CXCL13. Os objetivos secund??rios s??o descrever os achados USG de m??os em pacientes com AJ secund??ria a LES, comparar os achados USG dos pacientes com AJ com aqueles vistos em pacientes l??picos com artrite mas sem AJ e avaliar a correla????o entre os n??veis s??ricos de CXCL13 e a atividade de doen??a. Material e M??todos: Sessenta e quatro pacientes com l??pus eritematoso sist??mico foram selecionados, 32 com e 32 sem AJ. Cada paciente foi submetido a exame f??sico, exames laboratoriais (incluindo dosagem s??rica de CXCL13 por ELISA) e estudo ultrassonogr??fico de m??os e punhos. Hipertrofia sinovial, tenossinovite e eros??es foram avaliados de acordo com um sistema de classifica????o semi-quantitativo de 0-3. Os achados ultrassonogr??ficos foram correlacionados com os n??veis s??ricos de CXCL13, outros par??metros sorol??gicos e ??ndice de atividade da doen??a. Resultados: Sinovite foi encontrado em 25/64 pacientes (39%) e tenossinovite em 14/64 (22%). Estes achados foram mais freq??entes nos pacientes com AJ, particularmente tenossinovite (p = 0,002). O n??vel s??rico m??dio de CXCL13 foi de 20,16 pg / ml em toda a popula????o (23,2 pg / ml no grupo com AJ e 11,5 pg / ml no grupo sem AJ). Houve associa????o entre atividade de doen??a e n??veis elevados de CXCL13 ( p = 0,004). No entanto, nenhuma associa????o foi encontrada entre os n??veis s??ricos de CXCL13 e o item "artrite" do SLEDAI ou mesmo de edema articular ao exame f??sico e sinovite no estudo ultrassonogr??fico.Conclus??o: Os achados ultrassonogr??ficos articulares de pacientes com LES e AJ confirmam que sinovite e tenossinovite s??o mais comuns nesses pacientes. Al??m disso, n??veis s??ricos de CXCL13 est??o associados ?? atividade da doen??a no LES, mas n??o parece ser um biomarcador de artrite nesses pacientes.
APA, Harvard, Vancouver, ISO, and other styles
2

Fernandes, Elisabeth Gonzaga Canova. "Avaliação da influência da exposição à poluição atmosférica sobre o escore de atividade do lúpus eritematoso sistêmico (SLEDAI-2K) em crianças e adolescentes." Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/5/5141/tde-25112015-114302/.

Full text
Abstract:
Introdução: Muitos dos efeitos nocivos sobre a saúde humana são provocados por poluentes atmosféricos como as partículas menores que 10 micrômetros de diâmetro (material particulado - PM10). Essas partículas se originam principalmente das emissões de veículos automotores em áreas urbanas. Uma porção significativa do material particulado é constituída por sulfatos, nitratos, metais, hidrocarbonetos e outras substâncias adsorvidas em suas moléculas. A poluição do ar relacionada a emissões de fontes veiculares é um importante problema de saúde pública dos grandes centros urbanos sendo as crianças e adolescentes suscetíveis aos efeitos nocivos dessa poluição. No entanto, existem poucos estudos que avaliaram a associação entre a exposição à poluição do ar e doenças autoimunes nessa população, e para nosso conhecimento, nenhum estudo avaliou a influência dos poluentes atmosféricos sobre a atividade do lúpus eritematoso sistêmico juvenil (LESJ). Objetivos: (1). Avaliar a presença de associação entre variações agudas nas concentrações dos poluentes atmosféricos da Região Metropolitana de São Paulo (RMSP) e o risco de atividade da doença através do Índice de Atividade do Lúpus Eritematoso Sistêmico (SLEDAI-2K) em crianças e adolescentes com LESJ e (2). Avaliar a influência da exposição à poluição atmosférica dos 21 dias anteriores a cada consulta (estrutura de defasagem) sobre risco de atividade da doença através do SLEDAI-2K em crianças e adolescentes com LESJ. Métodos: Estudo longitudinal retrospectivo de painel realizado com base em 409 visitas consecutivas de pacientes com LESJ (critérios do American College of Rheumatology - ACR) que vivem na Região Metropolitana de São Paulo. A atividade da doença foi avaliada de acordo com o Índice de Atividade do Lúpus Eritematoso Sistêmico revisado em 2000 (SLEDAI-2K), e os valores de cada consulta foram divididos em dois grupos: SLEDAI 8. Concentrações diárias de material particulado (PM10), dióxido de enxofre (SO2), dióxido de nitrogênio (NO2), ozônio (O3) e monóxido de carbono (CO) foram avaliados nos 21 dias que antecederam as consultas médicas. Um modelo de equação de estimativa generalizada (EEG) foi utilizado para avaliar o impacto dessas medidas sobre o SLEDAI-2K, considerando os efeitos fixos para medições repetitivas. Os modelos foram ajustados para a velocidade de hemossedimentação (VHS), uso de corticosteróides (prednisona e dose cumulativa de prednisona), anti-maláricos, agentes imunossupressores, presença de infecção nos 20 dias anteriores à consulta médica, temperatura mínima e umidade relativa do ar. Resultados: PM10, NO2 e CO foram fatores de risco para a atividade do LESJ (SLEDAI-2K > 8) aproximadamente duas semanas após a exposição. Um aumento de 13,4 ?g / m3 na média móvel de PM10 (do lag12 ao lag15) foi associado a um aumento de 34% (95% intervalo de confiança - 7,0 - 68,0) no risco de SLEDAI-2K acima de 8. Conclusões: (1). Exposição à poluição atmosférica pode aumentar o risco de atividade da doença nos pacientes com LESJ que residem em grandes cidades e (2). Efeito da exposição à poluição do ar sobre o aumento da atividade do LESJ foi observado 13 dias após a exposição<br>Introduction: Many of the harmful effects on human health caused by atmospheric pollutants have been linked to particles smaller than 10 micrometers in diameter (PM10). These particles mainly originate from automotive vehicle emissions in urban areas. A significant portion of the particulate matter is composed of sulfates, nitrates, metals, hydrocarbons and other substances adsorbed in these molecules. Air pollution related to vehicular emission sources is an important public health problem in large cities, and children and adolescents are susceptible to the harmful effects of this pollution. However, there are few studies evaluating the association between exposure to air pollutants and autoimmune diseases in this population and to our knowledge, no study has assessed the influence of atmospheric pollutants on disease activity of childhood-onset systemic lupus erythematosus (C-SLE) patients. Objectives: (1). Evaluate the presence of association between acute variations in the concentrations of atmospheric pollutants in the Metropolitan Region of São Paulo (MRSP) and the risk of disease activity through the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) in children and adolescents with C-SLE and (2). Evaluate the influence of exposure to air pollution of 21 days prior to each consultation on risk of disease activity through the SLEDAI-2K in children and adolescents with C-SLE. Methods: A longitudinal panel retrospective study was carried out based on 409 consecutive visits of C-SLE patients (American College of Rheumatology - ACR criteria) living in the Metropolitan Region of São Paulo. Disease activity was evaluated according to Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and the patients were divided in two groups: SLEDAI 8. Daily concentrations of inhaled particulate matter (PM10), sulfur dioxide (SO2), nitrogen dioxide (NO2), ozone (O3) and carbon monoxide (CO) were evaluated on the 21 days preceding the medical visits. A generalized estimation equation (GEE) model was used to assess the impact of these measurements on the SLEDAI-2K score, considering the fixed effects for repetitive measurements. The models were adjusted for erythrocyte sedimentation rate (ESR), corticosteroid use (prednisone use and cumulative dose of prednisone), antimalarials, immunosuppressive agents, presence of infection 20 days preceding the medical appointment, minimum temperature and relative humidity. Results: PM10, NO2 and CO were risk factors for C-SLE activity (SLEDAI-2K > 8) approximately two weeks after exposure. A 13,4 ug/m3 increase in PM10 moving average (from lag 12 to lag 15) was associated to a 34 % (95% confidence interval - 7,0 - 68,0) increase in the risk of SLEDAI-2K above 8. Conclusions: (1). Exposure to atmospheric pollution may increase the risk of disease activity in patients with C-SLE residing in large cities and (2). Effect of exposure to air pollution on increasing JSLE activity was observed 13 days after exposure
APA, Harvard, Vancouver, ISO, and other styles
3

Neves, Taiana Fernandes Pinheiro. "Dislipidemia e lúpus eritematoso sistêmico: índices aterogênicos de risco cardiovascular, anticorpos antisaccharomyces cerevisae e iga anti-β2 glicoproteína I". Universidade Federal da Bahia, 2016. http://repositorio.ufba.br/ri/handle/ri/22867.

Full text
Abstract:
Submitted by Pós Imunologia (ppgimicsufba@gmail.com) on 2017-06-05T19:24:17Z No. of bitstreams: 1 Dissertação Taiana final corrigida 16.02.2017 (1).pdf: 1211793 bytes, checksum: a20533e20682931dfb2ee45359c2edcf (MD5)<br>Approved for entry into archive by Delba Rosa (delba@ufba.br) on 2017-06-07T14:02:20Z (GMT) No. of bitstreams: 1 Dissertação Taiana final corrigida 16.02.2017 (1).pdf: 1211793 bytes, checksum: a20533e20682931dfb2ee45359c2edcf (MD5)<br>Made available in DSpace on 2017-06-07T14:02:20Z (GMT). No. of bitstreams: 1 Dissertação Taiana final corrigida 16.02.2017 (1).pdf: 1211793 bytes, checksum: a20533e20682931dfb2ee45359c2edcf (MD5)<br>Capes<br>INTRODUÇÃO: O lúpus eritematoso sistêmico é uma doença reumática autoimune caracterizada por múltiplas manifestações clínicas e laboratoriais, entre estas, a dislipidemia. Contudo, a imunopatogenia desta alteração metabólica no LES ainda não é bem conhecida. OBJETIVO: O presente estudo investigou o envolvimento de anticorpos na patogênese da doença obstrutiva coronária crônica de pacientes portadores de LES de um serviço de reumatologia de Salvador-Bahia. Especificamente, investigou a presença de anticorpos IgA anti-β2GPI e IgG anti-Saccharomyces cerevisiae em pacientes lúpicos e buscou associar a soropositividade para estes anticorpos com achados clínicos e laboratoriais indicadores de doença obstrutiva coronária crônica e história de acidente cardiovascular. MATERIAL E MÉTODOS: Cento e cinquenta mulheres portadoras de LES foram incluídas no estudo e classificadas para dislipidemia a partir dos seus lipidogramas. A atividade do LES foi avaliada com o SLEDAI-2K. Foram determinados os seguintes índices aterogênicos de risco cardiovascular: razão apoB/apoA, índices I e II de Castelli (CT/HDL-C e LDL-C/HDL-C, respectivamente) e a razão TG/HDL-C. Anticorpos antinucleares foram detectados por IFI, enquanto anticorpos contra autoantígenos, anti-S. cerevisiae (ASCA) e IgA anti-β2GPI foram detectados por testes de ELISA indiretos. RESULTADOS: Cento e dezesseis de 151 pacientes (76,8%) eram dislipidêmicas. Destas, 13 tinham relato de evento cardiovascular (AVC = 12 e IAM = 01). Uma importante proporção dessas pacientes tinha atividade lúpica moderada a alta (69/116, 59,5%), observando-se nas mesmas, níveis baixos de HDL-C e índices aterogênicos de risco cardiovascular mais elevados. Os títulos de ANA foram mais altos nos pacientes dislipidêmicos, enquanto a prevalência e os níveis dos autoanticorpos contra autoantígenos, de C3, C4 e PCR foram semelhantes entre pacientes sem dislipidemia e dislipidêmicas. Existiu uma maior prevalência de ASCA nas pacientes lúpicas em relação às mulheres sem LES, mas não foram observadas diferenças na prevalência e níveis destes anticorpos nos dois grupos de lúpus. Anticorpos IgA anti-β2GPI foram também detectados de forma similar nestes grupos. Não existiram correlações entre ASCA e anticorpos IgA anti-β2GPI e SLEDAI, índices aterogênicos e níveis de PCR. CONCLUSÕES: A maioria das pacientes lúpicas dislipidêmicas apresenta índices aterogênicos de risco cardiometabólico elevados, sugerindo alta predisposição aos eventos cardiovasculares. Existe uma importante produção de anticorpos IgG anti-S. cerevisiae no LES, mas sem relação com dislipidemia ou atividade da doença, sugerindo uma homologia estrutural entre a manana da levedura e autoantígenos.<br>INTRODUCTION: Systemic lupus erythematosus is an autoimmune rheumatic disease characterized by multiple clinical manifestations, among them, dyslipidemia. However, the immunopathogenesis of this metabolic alteration in SLE is still not well known. OBJECTIVE: The present study investigated the involvement of antibodies in the pathogenesis of chronic obstructive coronary disease in female patients with SLE from a rheumatology service in Salvador-Bahia. Specifically, it examined the presence of anti-β2GPI IgA and anti-Saccharomyces cerevisiae IgG antibodies (ASCA) in lupus patients and sought to associate seropositivity to these antibodies with clinical and laboratory findings indicative of chronic obstructive coronary disease and history of a cardiovascular event. MATERIAL AND METHODS: One hundred and fifty-one women with SLE were included in the study and classified for dyslipidemia from their blood lipid profile. The SLEDAI-2K protocol measured the SLE activity. The following atherogenic indexes of cardiovascular risk were determined: apoB / apoA ratio, Castelli indexes I and II (CT / HDL-C and LDL-C / HDL-C, respectively) and TG / HDL-C ratio. Antinuclear antibodies were detected by an indirect fluorescent antibody test. Indirect ELISAs detected autoantigen antibodies, ASCA and anti-β2GPI IgA antibodies. RESULTS: One hundred and sixteen patients (76.8%) were dyslipidemic. Of these, 13 had a previous cardiovascular event (stroke = 12 and AMI = 01). A significant proportion of these patients had moderate to high lupus activity (69/116, 59.5%), with high levels of non-HDL-C and higher atherogenic cardiovascular risk rates. ANA titers were higher in dyslipidemic patients, while the prevalence and levels of autoantibodies against autoantigens and of C3, C4, and C-reactive protein were similar among patients with and without dyslipidemia. There was a higher prevalence of ASCA in lupus patients compared to women without SLE, but both lupus patients had similar prevalence and levels of these antibodies. Anti-β2GPI IgA antibodies were also detected similarly in these SLE groups. There was no correlation between SLEDAI and either ASCA and IgA anti-β2GPI antibodies, atherogenic indexes and CRP levels. CONCLUSIONS: The majority of dyslipidemic lupus patients present elevated atherogenic cardiometabolic risk, suggesting a high predisposition to cardiovascular events. There is a significant production of ASCA in SLE, but it is unrelated to dyslipidemia or disease activity, suggesting a structural homology between S. cerevisiae mannan and autoantigens.
APA, Harvard, Vancouver, ISO, and other styles
4

Hartmann, Lisandra Torres. "Avaliação do volume plaquetário médio em pacientes com lúpus eritematoso sistêmico." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2016. http://hdl.handle.net/10183/157942.

Full text
Abstract:
Introdução: O Lúpus eritematoso sistêmico (LES) é uma doença inflamatória autoimune crônica de etiologia ainda pouco conhecida, e de natureza pleomórfica, que intercala períodos de atividade e remissão. O desenvolvimento da autoimunidade no LES está associado à perda da tolerância imunológica e do controle imunorregulatório, tendo seus achados clínicos e laboratoriais variados. A atividade do LES pode ser medida pelo SLEDAI (systemic lupus erythematosus disease activity index) que é uma ferramenta complexa e que exige treinamento e conhecimento para sua aplicação. O volume plaquetário médio (VPM) é um marcador de ativação de plaquetas associado à inflamação, o que o torna um potencial candidato para a avaliação de atividade de doença no LES. Objetivos: Avaliar o VPM em pacientes com LES e comparar com indivíduos hígidos. Estudar a correlação entre o VPM e o índice de atividade de doença (SLEDAI) nos pacientes com LES. Analisar a correlação entre o VPM e a velocidade de sedimentação globular (VSG), a proteína C reativa (PCR), e os componentes do complemento C3 e C4 Métodos: Estudo transversal no qual foram incluídos 81 pacientes com LES segundo critérios de classificação diagnóstica do American College of Rheumatology (ACR), e 58 controles hígidos. Os pacientes foram selecionados consecutivamente por conveniência, de acordo com exames laboratoriais e SLEDAI devidamente calculados. As coletas foram realizadas entre outubro de 2015 e julho de 2016. LES ativo foi definido como SLEDAI>0 no momento da coleta. O VPM foi analisado no equipamento de automação Sysmex XE 5000. Resultados: O VPM estava reduzido nos pacientes com LES em atividade, quando comparado ao grupo de pacientes com LES inativo (10,0±0,7fL vs. 10,7±1,0fL, p=0,005). Existe uma fraca correlação inversa entre o valor do SLEDAI e o VPM (r=-0,29, p=0,009). Houve uma diferença significativa no VPM entre o grupo dos controles e os pacientes com LES ativo<br>Background Systemic Lupus Erythematosus (SLE) is an inflammatory autoimmune chronic disease etiology still unknown, and pleomorphic nature, which intersperses periods of activity and remission. The development of autoimmunity in SLE is related to loss of immunological tolerance and immunoregulatory control and clinical symptoms can be varied. The SLE activity can be measured by SLEDAI (systemic lupus erythematosus disease activity) which is a complex tool and it requires time and knowledge for your application. The MPV (mean platelet volume) is a marker of platelet activation and has been shown to be associated with inflammation, which makes it a potential candidate for use in the assessment of disease activity in SLE. In this study, we evaluated the MPV (Mean platelet volume) in healthy individuals and compared with SLE patients and correlate with SLEDAI VPM. Objectives: -To evaluate the MPV in SLE patients and compared with healthy individuals; to study the correlation between MPV and the SLEDAI patients with SLE and assess a possible correlation between MPV with erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement 3 (C3), and complement 4 (C4) Methods: This is a cross-sectional study in which 81 patients with SLE according to the American College of Rheumatology (ACR) diagnostic classification criteria and 58 healthy controls were included. Patients were selected for convenience, according to laboratory tests and SLEDAI duly calculated. The collections were carried out between October 2015 and July 2016. Active LES was defined as SLEDAI>0 at the time of collection. The VPM was analyzed in the Sysmex XE 5000 automation equipment. Results: In this study in patients with active SLE, the MPV is reduced when compared to the group of patients with inactive SLE [10.0±0.7fL vs. 10.7±1.0fL, p=0.005]. There is a weak inverse correlation between the SLEDAI value and the MPV (r=-0.29, p=0.009). There was a significant difference between the control group and the patients with active SLE (10.9 ±1.0fL vs. 10.0±0.7fL, p <0.001). In contrast, the MPV was similar between the control group and the group of patients with inactive SLE (10.9±1.0fLvs10.7±1.0fL, p=0.40). There was no correlation between MVP and CRP, ESR, C3 and C4. Conclusion: MPV is decreased in patients with active SLE and inversely correlated with SLEDAI. Despite the difference between MVP values, between active and inactive SLE patients, the results may not be clinically relevant. Prospective longitudinal studies are needed to better characterize the fluctuation of MPV in different states of disease activity to more clearly define the role of MPV in SLE.
APA, Harvard, Vancouver, ISO, and other styles
5

Camus, Jorge, and Angélica Gougain. "Slide Sledge." Tesis, Universidad de Chile, 2015. http://repositorio.uchile.cl/handle/2250/136980.

Full text
Abstract:
Tesis para optar al grado de Magíster en Marketing<br>Jorge Camus [Parte I], Angélica Gougain [Parte II No envía autorización para acceso a texto completo de su documento]<br>El producto es un innovador martillo de movimiento lineal llamado Slide Sledge que genera mejoras productivas en el mantenimiento de maquinaria pesada, permitiendo realizar esta labor de manera más segura, eficiente y productiva. Específicamente, en Chile está orientado a la minería y constructoras, ya que son compañías que poseen altos estándares de seguridad y por otra parte, en el caso de las mineras, dada la importancia económica de este rubro como pilar en la economía de Chile, siendo las empresas de mantención a faenas y constructoras, los clientes que comprarán y usarán este producto. Por otra parte, las tendencias de mercado analizadas nos entregan datos relevantes sobre el actual panorama en la minería, para las empresas de mantenimiento y para la construcción, hoy en día, la importancia está enfocada a reducir los costos, aumentar la productividad y a incorporar nuevas tecnologías que permitan mejorar los procesos realizándolos de manera más eficiente y segura. Este punto es fundamental para el lanzamiento al mercado de este producto, dado que, por su parte, las mineras son el principal foco de este trabajo y ellas suelen externalizan a proveedores el servicio de mantención de maquinarias, lo cual implica generar contratos que involucran multas millonarias por retrasos, entonces, sin duda que estas empresas están preocupadas hoy más que nunca de cada acción que desarrollan, dado el ambiente hostil y apretado actual del rubro, por lo tanto, este producto ayuda a estas empresas a centrarse en una estrategia de diferenciación pensando en un futuro más rentable. Frente a esto lo más eficiente es cuidar el trabajo realizado y disminuir con tendencia a cero cada falla o retraso. Por lo cual, este plan de marketing se centrará en lanzar al mercado este producto a las empresas de mantenimiento para el rubro de la minería Chilena como primer foco y como segundo las empresas constructoras, dado la similitud en el trabajo a realizar y la posibilidad de incluir esta aplicación.
APA, Harvard, Vancouver, ISO, and other styles
6

Musil, Martin. "Sleva z ceny stavebního díla." Master's thesis, Vysoké učení technické v Brně. Fakulta stavební, 2012. http://www.nusl.cz/ntk/nusl-225432.

Full text
Abstract:
The aim of the thesis is describe how discounts are formulated in construction work. Different types of discounts are discussed from the point of view of the constructor. Mechanisms of providing discounts and calculations of total discounts are studied. Contract and signing over the construction work are analysed, because of their importance to prevent disagreement between customer and constructor.
APA, Harvard, Vancouver, ISO, and other styles
7

Kess, Alexandra. "Johann Sleidan and the Protestant vision of history /." Aldershot, Hants, England ; Burlington, VT : Ashgate Pub, 2007. http://opac.nebis.ch/cgi-bin/showAbstract.pl?u20=9780754657705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kess, Alexandra H. "Johann Sleidan and the Protestant vision of history." Thesis, University of St Andrews, 2004. http://hdl.handle.net/10023/13238.

Full text
Abstract:
The main focus of interest in this PhD dissertation is the Reformation historian and diplomat Johann Sleidan (1506-1556). Born in Schleiden and brought up together with Strasbourg's famous Jean Sturm, Sleidan soon entered a period of active political life with his employment at the chancellory of Cardinal Jean Du Bellay in Paris in the mid-1530s. There and later in Strasbourg his main concern was to encourage a rapprochement or possible alliance between France and the German Protestants. It was also in Paris that Sleidan discovered history as his second passion. After translating key French historians into Latin, Sleidan moved on to produce his own works of a political-historical nature. His main work, De statu religionis et reipublicae Carolo Quinto Caesare commentarii, 'Commentaries on religion and state under Emperor Charles V', published in 1555, was initially commissioned by the Schmalkaldic League as the official history of the Reformation. Despite early hostile reactions, this history was an immediate success with the buying public, published in numerous editions and by the year 1560 circulated in six different languages. Chapters one to three explore Sleidan's biography in depth. The collection and analysis of contemporary correspondence has provided the cornerstone for a new narrative of Sleidan's life in the second half of this thesis I move to a detailed study of his principal published works. Chapter four concentrates on Sleidan's main work, the Commentaries. After placing this history in the context of contemporary German history writing, I examine this work in detail, treating its genesis, character, and methodology. I examine the unexpectedly hostile reactions to the first edition and its very rapid success with purchasers. I then move on to consider the longer-term reaction to Sleidan's great work, first in Germany and then in France. I explore the controversies aroused by Sleidan's work, among both Catholics and Protestants, and in contrast, the great respect for his scholarship that also straddled the religious confessions. Sleidan provided the context through which I have been able to analyse the life of a scholar in the sixteenth century, and the works of one of the foremost historians of the new evangelical movement. His life and his works have not, until this point, been placed in a broader context. His work as a translator and historian provides an excellent example of the movement of text around the cultural communities of Europe. Sleidan played a vital part in this process by offering Latin translations of leading French historians which would later be translated into other languages, and by publishing his own works in German or Latin, which were then translated into many other vernaculars. But Sleidan was also engaged in the world of public affairs. Sleidan's position in Du Bellay's chancellery in Paris has provided a new picture of French evangelism. This contact was not given up when Sleidan moved to Strasbourg. The Franco-imperial city has been shown again as one of the cultural centres of Europe from where an intellectual and political elite operated on a cross-national and cross-confessional level. Strasbourg with its francophone scholars was also the Schmalkaldic League's gateway to France. Sleidan's connections as a diplomat linked Germany and France, and have formed the basis for a new study of those in the Franco-German world who shared Sleidan's concerns to promote peace across the religious divide.
APA, Harvard, Vancouver, ISO, and other styles
9

Sleman, Ayman [Verfasser]. "SOA Operating System for Distributed Resource-Constrained Embedded Devices / Ayman Sleman." München : Verlag Dr. Hut, 2012. http://d-nb.info/1028783957/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Khuluq, Lathiful. "Democracy, participation, and empowerment: poverty alleviation programs in Sleman, Yogyakarta, Indonesia." Thesis, McGill University, 2009. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=32533.

Full text
Abstract:
Abstract Keywords: poverty; micro credit; good governance; international social work; Indonesia. Indonesia has experienced a shift from authoritarianism to democracy since the late 1990s. After the severe economic crisis of 1997, which ultimately forced Soeharto to relinquish power, Indonesia embarked on a more liberal and participatory form of democracy. To overcome the economic and social crisis that caused many to fall into poverty, the new government administration launched a number of poverty alleviation programs. This dissertation explores one such effort, namely, the Program Penanggulangan Kemiskinan di Perkotaan (P2KP), an extensive scheme that utilized democratic, participatory, and empowerment approaches to help the poor deal with unemployment and other problems of poverty. Using qualitative methodology, this study has explored and examined the process and outcomes of poverty alleviation programs in several villages in the southern parts of Sleman District, Yogyakarta Special Province, Indonesia, from February-May 2006. The thesis begins with a review of the literature on the factors leading to poverty, development and participation, globalization and its negative impacts, and various strategies for ending the problems of poverty, such as multiple occupations, empowerment, and human capital improvement. Findings were based on interviews, observation, and reviews of written documents concerning the P2KP poverty alleviation programs. Over 30 individuals were interviewed, ranging from government officials to facilitators and organizers of the programs, non-government activists, and the poor who benefitted or were excluded from the programs. The process of the es<br>Résumé Mots clefs : pauvreté, micro-crédit, bonne gouvernance, travail social international, Indonésie L'Indonésie a subi un décalage de l'autoritarisme à la démocratie depuis la fin des années 90. Après la crise économique sévère de 1997, ce qui a enfin poussé Soeharto de renoncer au pouvoir, l'Indonésie s'est embarque dans une forme de démocratie plus libérale et participative. Pour surmonter la crise économique et sociale qui a jeté plusieurs dans la pauvreté, la nouvelle administration gouvernementale a lancé nombre de programmes destinés à atténuer la pauvreté. Cette dissertation vise à explorer un de ces efforts, c'est-à-dire, le Program Penanggulangan Kemiskinan di Perkotaan (P2KP), un vaste projet qui a employé des approches démocratiques, participatives et autonomisantes pour aider les démuni s à affronter la chômage et d'autres problèmes liés à la pauvreté. En employant une méthodologie qualitative, cette étude a enquêté et examiné le processus et les résultats des programmes d'atténuation de la pauvreté dans plusieurs villages du secteur sud du district de Sleman, province spéciale de Yogyakarta, Indonésie, en février-mai 2006. La dissertation commence avec une revue de la littérature sur les facteurs qui mènent à la pauvreté, le développement et la participation, la mondialisation et ses impacts négatifs, et les stratégies multiples pour mettre fin aux problèmes de la pauvreté, tels que des emplois multiples, l'autonomisation et l'amélioration de capital humain. Les résultats sont fondés sur des entrevues, l'observation et la documentation écrite par égard aux programmes d'atténuation de pauvret
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "SLEDAI"

1

Peršak, Tone. Sledi. Prešernova družba v Ljubljani, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Križnar, Tomo. Samotne sledi. Samozal., 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sitʹko, Zdislav. Po sledam Litvy. Kharvest, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dubovoĭ, Ėdvard Iosifovich. Po sledam nevidimok. Izd-vo "Znanie", 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Po sledam minuvshego. Tatarskoe knizhnoe izd-vo, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Angarskai︠a︡, Marii︠a︡. Po sledam ott︠s︡a. INION RAN, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Belkin, R. S. Po sledam nevidimki. 2nd ed. "Adolat", 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

David, McNeil. Po sledam angela. "Tekst", 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sergeĭ, Tiktin, ed. Po gori︠a︡chim sledam. Zhurnal "Neva", 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bekuzarov, A. Po sledam Tatarkana. 2nd ed. Ir, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "SLEDAI"

1

Zapf, Ashley D., and Joan P. Joyce. "Ice Sled Hockey (Sledge Hockey Outside the United States)." In Adaptive Sports Medicine. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56568-2_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Stock, D., R. Fabisiak, and A. Niezgoda. "Experience with the Sledge Prosthesis." In Total Knee Replacement. Springer London, 1991. http://dx.doi.org/10.1007/978-1-4471-1825-1_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Stewart, A. D. "The Sleat and Torridon Groups." In Later Proterozoic Stratigraphy of the Northern Atlantic Regions. Springer US, 1988. http://dx.doi.org/10.1007/978-1-4615-7344-9_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Tahan, Mary R. "Twenty-One Sledge Dogs for Douglas Mawson." In The Return of the South Pole Sled Dogs. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-65113-8_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tahan, Mary R. "Introduction: Dogs, the Arctic, and Amundsen’s Clandestine Switch to the Antarctic." In Roald Amundsen’s Sled Dogs. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-02692-9_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tahan, Mary R. "The Females and the Mother Ship: Woman Shall Not Come on Board." In Roald Amundsen’s Sled Dogs. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-02692-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tahan, Mary R. "Maren and Her Sons in Madeira: Enduring the Heat." In Roald Amundsen’s Sled Dogs. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-02692-9_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tahan, Mary R. "The Births and Deaths of October." In Roald Amundsen’s Sled Dogs. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-02692-9_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tahan, Mary R. "The Lady and the Sea." In Roald Amundsen’s Sled Dogs. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-02692-9_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tahan, Mary R. "Christmas Among the Ice Floes." In Roald Amundsen’s Sled Dogs. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-02692-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "SLEDAI"

1

Touma, Z., D. Gladman, J. Su, N. M. Anderson, and M. B. Urowitz. "FRI0395 Sle disease activity index glucocorticoid index (SLEDAI-2KG) identifies more responders than sledai-2k." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5519.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Urowitz, M., DD Gladman, J. Su, NM Anderson, and Z. Touma. "S1D:5 Sle disease activity index glucocorticosteroid index (sledai-2kg) identifies more responders than sledai-2k." In 11th European Lupus Meeting, Düsseldorf, Germany, 21–24 March 2018, Abstract presentations. Lupus Foundation of America, 2018. http://dx.doi.org/10.1136/lupus-2018-abstract.5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sari, Selma, Bahar Artim Esen, Ahmet Gül, Lale Öcal, and Murat İnanç. "P181 Comparison of SLEDAI-2K and SLEDAI-2KG (glucocorticoid) indexes in patients with systemic lupus erythematosus (SLE)." In 12th European Lupus Meeting. Lupus Foundation of America, 2020. http://dx.doi.org/10.1136/lupus-2020-eurolupus.223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, K., S. Boyd, F. Petitjean, et al. "AB0570 Association between sledai-2k domains and organ damage accrual." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.5261.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Villarreal-Alarcόn, MA, JA Esquivel-Valerio, D. Vega-Morales, et al. "AB0023 Association between mex-sledai and infections with mbl structural and promoter genotypes in mexican-mestizo patients." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3304.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Regola, Francesca, Silvia Piantoni, Laura Andreoli, et al. "FRI0207 BASELINE LEVELS OF BAFF, APRIL AND CD8+ EFFECTOR MEMORY CELLS AS PREDICTORS OF SLEDAI RESPONSE TO BELIMUMAB THERAPY." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.4369.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Regola, Francesca, Silvia Piantoni, Laura Andreoli, et al. "P136 SLEDAI response prediction to belimumab therapy by baseline levels of BLyS, APRIL and CD8+ effector memory T-cells." In 12th European Lupus Meeting. Lupus Foundation of America, 2020. http://dx.doi.org/10.1136/lupus-2020-eurolupus.180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Touma, Zahi, Dafna D. Gladman, Kaiyin Fei, et al. "10 Performance of SLEDAI-2K Responder Index-50 in a Randomized Placebo-Controlled Trial with Ustekinumab (UST) in Systemic Lupus Erythematosus." In 13th International Congress on Systemic Lupus Erythematosus (LUPUS 2019), San Francisco, California, USA, April 5–8, 2019, Abstract Presentations. Lupus Foundation of America, 2019. http://dx.doi.org/10.1136/lupus-2019-lsm.10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Touma, Z., D. Gladman, J. Su, and M. Urowitz. "11 Development and initial validation of a novel lupus disease activity index to account for glucocorticoids: SLEDAI-2K glucocorticoids index (SGI)." In LUPUS 2017 & ACA 2017, (12th International Congress on SLE &, 7th Asian Congress on Autoimmunity). Lupus Foundation of America, 2017. http://dx.doi.org/10.1136/lupus-2017-000215.11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jesus, D., M. Rodrigues, A. Matos, C. Henriques, J. da Silva, and L. Inês. "OP0206 Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.3895.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "SLEDAI"

1

Farkas, Zoltan D. Increasing SLEDed Linac Gradient. Office of Scientific and Technical Information (OSTI), 2001. http://dx.doi.org/10.2172/798900.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lippmann, B. A. Equivalent circuit analysis of sled. Office of Scientific and Technical Information (OSTI), 1986. http://dx.doi.org/10.2172/5596307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Decker, Franz-Josef. High Current, Long Beam Pulse with SLED. Office of Scientific and Technical Information (OSTI), 1999. http://dx.doi.org/10.2172/10200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Decker, Franz-Josef. Low Current, Long Beam Pulse with SLED. Office of Scientific and Technical Information (OSTI), 1999. http://dx.doi.org/10.2172/10049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Farkas, Z. Effect of Sled Cavity Temperature Changes on Effective Accelerating Field. Office of Scientific and Technical Information (OSTI), 2006. http://dx.doi.org/10.2172/882199.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Furlow, John S. Parametric Dynamic Load Prediction of a Narrow Gauge Rocket Sled. Defense Technical Information Center, 2006. http://dx.doi.org/10.21236/ada466902.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hirshfield, Jay, L. Electron-Beam Switches For A High Peak Power Sled-II Pulse Compressor. Office of Scientific and Technical Information (OSTI), 2015. http://dx.doi.org/10.2172/1227594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Itagaki, Kazuhiko, Niklaus P. Huber, and George E. Lemieux. Dynamic Friction of a Metal Runner on Ice. 1. Model Sled Test. Defense Technical Information Center, 1989. http://dx.doi.org/10.21236/ada211498.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

SHAFFER, Winston J., and II. Noise Assessment of the Rocket Sled Test Track Operation at Holloman AFB, New Mexico. Defense Technical Information Center, 1988. http://dx.doi.org/10.21236/ada201279.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wilkins, Justin, Jarod Norton, and G. Roegner. Monitoring a nearshore beneficial use site : application of a benthic sled and video annotation. Engineer Research and Development Center (U.S.), 2019. http://dx.doi.org/10.21079/11681/31593.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography